Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies.
D000906:Antibodies / Q000008:administration & dosage*; D002272:Carcinoembryonic Antigen / Q000276:immunology; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000628:therapy*; D004307:Dose-Response Relationship, Radiation; D005293:Ferritins / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007167:Immunotherapy / Q000379:methods; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000628:therapy*; D014057:Tomography, X-Ray Computed
D000906:Antibodies; D002272:Carcinoembryonic Antigen; D007074:Immunoglobulin G; D007457:Iodine Radioisotopes; D005293:Ferritins